##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-KT
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from January 1, 2010 to September 30, 2010
 Commission file number 0-6428
 
 Robertson Global Health Solutions Corporation
  Nevada
(State or other jurisdiction of 
incorporation or organization)
    
    88-0105586
(I.R.S. Employer
Identification Number)
 4215 Fashion Square Blvd., Suite 3
Saginaw, Michigan 48603
 (989) 799-8720
  Common Stock, par value $.001
 Yes o No þ
 Yes o No þ
 Yes þ No o
 o Yes o No
 þ
  Large Accelerated Filer o
    
    Accelerated filer o
    
    Non-accelerated filer o
    
    Smaller reporting company þ
 Yes o No þ
   DOCUMENTS INCORPORATED BY REFERENCE




---



##### 



TABLE OF CONTENTS
 PagePART IITEM 1. Business
    
    
    4ITEM 1A. Risk Factors
    
    
    17ITEM 1B. Unresolved Staff Comments
    
    
    23ITEM 2. Properties
    
    
    23ITEM 3. Legal Proceedings
    
    
    23ITEM 4. (Removed and Reserved)
    
    
    24PART IIITEM 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities
    
    
    24ITEM 6. Selected Financial Data
    
    
    25ITEM 7. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    25ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk
    
    
    30ITEM 8. Financial Statements and Supplementary Data
    
    
    30ITEM 9. Changes In and Disagreement With Accountants on Accounting and Financial Disclosure
    
    
    30ITEM 9A Controls and Procedures
    
    
    30ITEM 9B. Other Information
    
    
    32PART IIIITEM 10. Directors, Executive Officers and Corporate Governance
    
    
    32ITEM 11. Executive Compensation
    
    
    32ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters
    
    
    32ITEM 13. Certain Relationships and Related Transactions and Director Independence
    
    
    32ITEM 14. Principal Accounting Fees and Services
    
    
    32PART IVITEM 15. Exhibits, Financial Statement Schedules
    
    
    33Financial Statements
    
    
    F-1SignaturesExhibit 23.1Exhibit 23.2Exhibit 31.1Exhibit 31.2Exhibit 32.1
  Forward Looking Statements
 Certain statements in this report may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The terms may, should, could,
anticipate, believe, continues, estimate, expect, intend, objective, plan,
potential, project and similar expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and involve risks, uncertainties, and
assumptions that are difficult to predict. These statements are based on managements current
expectations, intentions, or beliefs and are subject to a number of factors, assumptions, and
uncertainties that could cause actual results to differ materially from those described in the
forward-looking statements. Factors that could cause or contribute to such differences or that
might otherwise impact the business include the risk factors set forth in Item 1A of this Form
10-KT. We undertake no obligation to update any such factor or to publicly announce the results of
any revisions to any forward looking statements contained herein whether as a result of new
information, future events, or otherwise.
  2




---



##### Table of Contents



PART I
 
 ITEM 1.
    
    BUSINESS
 Overview
      3




---



##### Table of Contents



The Healthcare Information Systems Industry
      4




---



##### Table of Contents



Our Technology
 Development and Description
      
    
    Guided diagnostics, treatment options, and referrals.
 
    
    An integrated Personal Health Record (PHR) capability combined with an interactive
medical reference tool.
 
    
    A module for managing and tracking disease occurrence and public health initiatives in
both developed and emerging countries.
 
    
    A chronic disease management module that provides push-based medicine including Short
Message Service (SMS) alerts, follow-up and appointment notifications, as well as
personalized health tips.
 
    
    A patient treatment adherence module with personalized health tips.
    5




---



##### Table of Contents



Stage of Product Development
    Awards, Testimonials and Research
   Steve Ballmer, CEO
 Microsoft
   Amit Mital, Corporate VP  Microsoft Startup Business Group  mHealth Summit 2009, Washington DC
  Dr. Bill Crounse  Worldwide Director of Health for Microsoft Corporation.
  Dr. M.U.R. Naidu, Dean of the School of Medicine  Nizams Institute of Medical Sciences  Hyderabad, India
  Dr. David Heckerman, Director of Research  Microsoft Corporation
  6




---



##### Table of Contents




    
    A study in India in 2009 showed that health extension workers using RHealth Advisor were
more accurate than those using their standard paper method. With the RHealth Advisor
software their diagnosis matched a physician diagnosis 82.54% of the time, but when they
used their standard paper method of diagnosing, they only matched the physician diagnosis
54.58% of the time. To our knowledge this is the first time a tool like ours has been able
to verify that it can improve diagnostic accuracy of a health extender.
 
    
    In a 2010 side by side comparison study using the same disease, RHealth Advisor,
configured as a mobile solution using the NxOpinion platform on a mid-level phone,
outperformed WebMD using a smartphone, by diagnosing more accurately and with fewer
clicks.
 
    
    A study with Nizams Institute of Medical Sciences reported in 2009 that Multi-Purpose
Health Assistants (MPHAs) in India collected 57% more findings per case and 2,000% more
history items per case when using NxOpinion versus the normal paper method.
 
    
    A health extension worker assessment study (supported by Bill & Melinda Gates
Foundation) showed health workers and Accredited Social Health Activists (ASHAs) are well
suited to use RHealth Advisor.
 Technology Ownership/Licensing
      7




---



##### Table of Contents



Our Product Solutions
  NxOpinion Medical Screening Application
  Chronic Disease Management Application 
  8




---



##### Table of Contents



Treatment Adherence Application 
 Electronic Health Record Application 
 RHealth Advisor Health Tips 
   Market Overview and Opportunity
   
    
    Developing Countries assist health care workers to extend medical intervention where
there is limited or no availability of physicians.
 
    
    Emerging Markets to improve effectiveness in determining diagnoses and establishing
standardized treatment regimens.
 
    
    Mature Markets to drive efficiency into the healthcare system, reducing costs and
improving treatment adherence.
  9




---



##### Table of Contents




    
    Customer Segment
 
    
    Consumers  for pre-screening, chronic disease management and treatment adherence
 
    
    Hospital Systems and Patient Care Facilities  to increase throughput
and efficiency, for triage and treatment management
 
    
    Clinics and Physician Groups  for triage and treatment management
    
    National Health Programs  for pre-screening and chronic disease treatment management
    
    Non-Government Organizations  to identify health trends, disease eradication and data storage
 
    
    Strategic Partners, Collaborators and Integrators
 
    
    Insurance Carriers  for pre-screening and test validation
    
    Pharmaceutical Research  accumulate compound and outcomes data analysis
    
    Government Organizations  to identify health trends and delivery enhancements
 
    
    Electronic Health Record Providers  for repository storage of medical
records and linking to treatment and treatment management
 
    
    Device Industry Partners  with hardware for field data capture
 
    
    Third Party Service Providers  to assist in process management to
increase efficiency and accuracy
 
    
    Technology Partners  for integration of services
    
    Regional Distributors  to centralize and standardize product and service offerings
       10




---



##### Table of Contents




    
    Millions of rural healthcare workers are needed to serve more than 2.5 billion people in
the developing and emerging countries of Asia, Africa and South America. India alone is
seeking to train 250,000 first level workers to improve access to healthcare to over 500
million people. The funding for technology in these areas comes from governments and
charitable organizations and we plan to support these efforts globally. Consumers in these
markets are prime candidates for targeted marketing by pharmaceutical, biotechnology and
medical device companies that seek an efficient and cost-effective method to target
customers requiring their products. We believe that traditional advertising is ineffective
in these markets. Through mobile phones we can deliver targeted information to people in
need of healthcare services.
 
    
    Through collaborations with other companies, such as Microsoft Corporation and Montana
Healthcare Solutions, we expect to participate in a substantial developing market to allow
individuals to manage their health information and associate with providers to more
effectively manage their care. The goal of the governments in these emerging countries is
to use technology to reduce costs while improving care, as well as having the ability to
collect and store data that can be used for public health planning. We offer several
modules, with our data collection and diagnostic information typically being the main
offerings for joint marketing with partners. The population in the countries initially
being targeted in this partnership exceeds 200 million.
 
    
    We enrich the quality and relevance of health information that may be delivered to
consumers, physicians and other healthcare professionals, employers and health plans.
Unlike traditional delivery methods such as WebMD, we offer the ability to interact with a
knowledge management system to create a diagnosis based on relevant data. Whether as a
stand-alone website or as an engine powering the offerings of other sites, we believe we
have an important role in supercharging the health information marketplace.
  
    
    The 30,000 hospitals in the U.S. and many more worldwide that are candidates for case
management and clinical decision tracking which can benefit from our other modules. Many
are being required to upgrade HIS systems to meet new regulations and are seeking
cost-effective tools, such as ours, to reduce the incidence of misdiagnosis and minimize
unnecessary tests or procedures.
 
    
    Practicing physicians and clinics that wish to check or confirm diagnoses thus reducing
misdiagnosis error rates and minimize unnecessary tests or procedures. There are over
600,000 physicians and surgeons in the U.S. alone and many more worldwide.
 
    
    As a tool for medical training and education. Our system can become an integral part of
medical student training, allowing students to quickly access information and self-check
their diagnoses. We believe our solution can be an invaluable tool to help medical students
learn the next question to ask in order to complete an accurate diagnosis. There are
approximately 160 medical schools in the U.S. and WHO recognized over 1,600 international
schools as of 2000.
 
    
    Benefit managers who work to optimize care by identifying best practices and reducing
unnecessary procedures.
 Our Strategy and Collaborations
 Strategy
   11




---



##### Table of Contents



Collaborations and Integrations
        12




---



##### Table of Contents



Competition
   
    
    Scalability  the ability to scale to large national health systems throughout the
world.
 
    
    Adaptability  ability to adapt to increasingly complex and changing healthcare
systems.
 
    
    Compatibility  ability to work seamlessly with a diverse range of input devices
and back-end systems.
 
    
    Functionality  ability to offer a wide scope of services to meet healthcare needs.
 
    
    Performance  ability to perform rapidly given the large scale of functionality.
 
    
    Security  ability to protect highly sensitive consumer information.
 
    
    Reliability  ability to provide predictable and repeatable highly relevant
diagnosis and treatment information.
 
    
    Relationships with large healthcare organizations and corporations  we have
demonstrated our ability to work with the largest organizations in the world.
    13




---



##### Table of Contents



Government Regulation
    United States Food and Drug Administration
   
    
    establishment registration and device listing with the FDA;
 
    
    the Quality System Regulation, or QSR, which requires manufacturers, including
third-party or contract manufacturers, to follow stringent design, testing, control,
documentation, and other quality assurance procedures during all aspects of
manufacturing;
 
    
    labeling regulations and FDA prohibitions against the advertising and promotion of
products for uncleared, unapproved off-label uses and other requirements related to
advertising and promotional activities;
 
    
    medical device reporting regulations, which require that manufacturers report to
the FDA if their device may have caused or contributed to a death or serious injury or
malfunctioned in a way that would likely cause or contribute to a death or serious
injury if the malfunction were to recur;
 
    
    corrections and removal reporting regulations, which require that manufacturers
report to the FDA any field corrections and product recalls or removals if undertaken
to reduce a risk to health posed by the device or to remedy a violation of the FDCA
that may present a risk to health; and
 
    
    post-market surveillance regulations, which apply when necessary to protect the
public health or to provide additional safety and effectiveness data for the device.
  14




---



##### Table of Contents



Privacy and Security Regulations.
  State Laws
  Medical Professional Regulation
  Other Requirements
    15




---



##### Table of Contents



Executive Officers
  Joel C. Robertson
 Melissa A. Seeger
 Employees
  Available Information
  
 ITEM 1A.
    
    RISK FACTORS
 In addition to the information contained elsewhere in this annual report, you should consider
carefully the following risk factors related to the Company. If any of the risks described below
actually occur, our business, financial condition, results of operations, cash flows and stock
price could be materially adversely affected. This annual report also contains forward-looking
statements that involve risks and uncertainties. Our actual results could differ materially from
those anticipated in these forward-looking statements as a result of certain factors, including the
risks faced by us described below and elsewhere in this annual report.
  16




---



##### Table of Contents



Risk Factors Relating to Our Business
 We are a development stage company.
 We have a history of losses and may incur future losses.
 Our independent auditors have expressed substantial doubt about our ability to continue as a
going concern
 We may need additional financing to continue our operations
 We are dependent upon key personnel and consultants.
  17




---



##### Table of Contents



We are controlled by our current officers, directors and principal stockholders.
 Conflicts of interest may arise relating to our technology license and other affiliate
arrangements.
 We must develop a customer base and collaborations in order to grow our business.
 
    
    our ability to customize and introduce products that have the features required by
particular customers;
 
    
    our ability to develop relationships with customers and collaborators that will lead
to use of our products by end users;
 
    
    our ability to develop new markets for our products; and
    
    our ability to develop international product distribution directly or through collaborative partners.
 Healthcare service providers and users may not accept our products.
 We may not be able to adequately enhance our products
 Our products may not perform as projected
  18




---



##### Table of Contents



We face intense competition.
 We cannot predict our future operating results. Our quarterly and annual results will likely
be subject to fluctuations caused by many factors, any of which could result in our failure to
achieve our expectations.
 
    
    our ability to develop and supply our software products and solutions to collaboration
partners and customers;
 
    
    market acceptance of, and changes in demand for, our software products;
    
    gains or losses of significant customers, collaborators or strategic relationships;
    
    the availability, pricing and timeliness of licensing of our products by customers;
 
    
    timing of new technological advances, product announcements or introductions by us, by
our licensees and by our competitors;
 
    
    product obsolescence and the management of product implementations and transitions;
    
    unpredictable installation, service or software warranty costs;
    
    installation or order delays by customers;
    
    general healthcare industry conditions, including changes in demand;
 
    
    general economic conditions that could affect the timing of customer orders and capital
spending and result in order cancellations or rescheduling; and
 
    
    general political conditions in this country and worldwide that could affect spending
for the products that we intend to offer.
  Our expenses may vary from period to period, which could affect quarterly results and our
stock price.
 
    
    the timing and extent of our research and development efforts;
    
    marketing, sales and licensing costs;
    
    investments and costs of maintaining or protecting our intellectual property;
    
    the extent of marketing and sales efforts and costs thereof to promote our products and technologies; and
    
    the timing of personnel and consultant hiring.
 Our products are subject to government regulation.
  19




---



##### Table of Contents



Our intellectual property may not be fully protected.
 There is widespread uncertainty in the U.S. healthcare industry.
 Our business may expose us to potential product liability risks.
 Inadequate internal controls and accounting practices could lead to errors, which could
negatively impact our business, financial condition, results of operations and cash flows.
 Risk Factors Relating to Our Common Stock
 There can be no assurance that an active trading market for shares of our common stock will
develop.
  20




---



##### Table of Contents



We cannot predict the price range or volatility of our common stock and sales of a substantial
number of shares of our common stock may adversely affect the market price of our common stock.
 
    
    general economic, market and political conditions;
 
    
    quarterly variations in results of operations or results of operations that are below
public market analyst and investor expectations;
 
    
    changes in financial estimates and recommendations by securities analysts;
    
    operating and market price performance of other companies that investors may deem comparable;
    
    press releases or publicity relating to us or our competitors or relating to trends in our markets; and
    
    sales of common stock or other securities by insiders.
   Penny Stock Regulations Affect Our Stock Price, Which May Make It More Difficult For Investors
To Sell Their Stock.
 We may issue additional common stock in the future. The issuance of additional common stock
may reduce the value of your common stock.
 Sales of common stock issuable on the exercise of any existing or future options or warrants
may lower the price of our common stock.
  21




---



##### Table of Contents



We may issue preferred stock in the future, and the terms of the preferred stock may reduce
the value of your common stock.
 The payment of dividends will be at the discretion of our Board of Directors.
 Our inability to comply with internal control requirements included in Section 404 of the
Sarbanes-Oxley Act of 2002 could have a negative impact on our stock price.
 
 ITEM 1B.
    
    UNRESOLVED STAFF COMMENTS
  
 ITEM 2.
    
    PROPERTIES
   
 ITEM 3.
    
    LEGAL PROCEEDINGS
   22




---



##### Table of Contents



ITEM 4.
    
    (REMOVED AND RESERVED)
 
 PART II
 
 ITEM 5.
    
    MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES
 Market Information
   Bid QuotationsHigh
    
    
    LowYear Ended September 30, 2009First Quarter
    
    $
    4.50
    
    
    $
    3.00Second Quarter
    
    $
    3.75
    
    
    $
    3.00Third Quarter
    
    $
    3.75
    
    
    $
    3.00Fourth Quarter
    
    $
    3.00
    
    
    $
    0.00Nine Months Ended September 30, 2010First Quarter
    
    $
    0.00
    
    
    $
    0.00Second Quarter
    
    $
    5.625
    
    
    $
    0.00Third Quarter
    
    $
    4.50
    
    
    $
    0.00
  Holders
  Dividends
   23




---



##### Table of Contents



Equity Compensation Plan Information
  Number of securitiesremaining available forNumber of securities to be
    
    
    Weighted-average exercise
    
    
    future issuance underissued upon exercise of
    
    
    price of outstanding
    
    
    equity compensation plansoutstanding options,
    
    
    options, warrants and
    
    
    (excluding securitieswarrants and rights
    
    
    rights
    
    
    reflected in column (a))Plan Category
    
    (a)
    
    
    (b)
    
    
    (c)Equity compensation
plans approved by
security holders
(1)
    
    
    590,078
    
    
    $
    3.22
    
    
    
    833,600Equity compensation
plans not approved
by security holders
    
    
    -0-
    
    
    
    
    
    
    
    -0-Total
    
    
    590,078
    
    
    $
    3.22
    
    
    
    833,600
 (1)
    
    In February 2010, our Board of Directors and Stockholders approved the Stock Incentive Plan of
2010 (the 2010 Incentive Plan) authorizing the grant of equity-based incentives to employees and
consultants including stock options, stock appreciation rights, restricted stock units, restricted
stock, stock awards and other awards on the lesser of (a) on a cumulative basis 15% of the
aggregate shares of our common stock issued and outstanding at any grant date (currently limited to
the maximum 1,400,000 shares) or (b) 1,400,000 shares. The Incentive Plan terminates in February
2020. Recent Sales of Unregistered Securities
  Issuer Purchases of Equity Securities
  
 ITEM 6.
    
    SELECTED FINANCIAL DATA
  
 ITEM 7.
    
    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 You should read the following discussion in conjunction with the financial statements and other
financial information included elsewhere in this transition report. The following discussion may
contain forward-looking statements that reflect our plans, estimates and beliefs. Our actual
results could differ materially from those discussed in these forward-looking statements. Factors
that could cause or contribute to these differences include, but are not limited to, those
discussed below and elsewhere in this information statement, particularly in Risk Factors.
 Overview
   24




---



##### Table of Contents



Recent Events
    Overall Performance
  Critical Accounting Policies and Estimates
   25




---



##### Table of Contents



Real estate  Fair Value Measurements and Disclosure
  Stock-based compensation CompensationStock Compensation
 Reverse acquisition accounting Business Combinations
   26




---



##### Table of Contents



Facility exit liability Exit or Disposal Cost Obligations
 Income taxes
  Comparison of Operating Results for the Nine Months Ended September 30, 2010 compared to the year
ended December 31, 2009
 Revenues
 Product and content development expenses
   Selling, general and administrative expenses
  27




---



##### Table of Contents



Impairment expense
 Other income (expenses)
 Net loss
 Liquidity and Capital Resources
    Effects of Inflation
   28




---



##### Table of Contents



Recent Accounting Pronouncements
  
 ITEM 7A.
    
    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
  
 ITEM 8.
    
    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
  
 ITEM 9.
    
    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
  
 ITEM 9A.
    
    CONTROLS & PROCEDURES
  Evaluation of Disclosure Controls and Procedures
   Managements Report on Internal Control Over Financial Reporting
   29




---



##### Table of Contents



1.
    
    We do not have sufficient segregation of duties within accounting functions,
which is a basic internal control. Due to our size and nature, segregation of all
conflicting duties including the initiation of transactions, the custody of assets and
the recording of transactions that should be performed by separate individuals may not
currently be economically feasible in the immediate future.
 2.
    
    We lacked independent oversight by an audit committee of independent members of
the Board of Directors throughout the year.
    Inherent Limitations on Effectiveness of Controls
   30




---



##### Table of Contents



Changes In Internal Control Over Financial Reporting
  
 ITEM 9B.
    
    OTHER INFORMATION
 Termination of a Material Definitive Agreement
  
 PART III
  
 ITEM 10.
    
    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
  
 ITEM 11.
    
    EXECUTIVE COMPENSATION.
  
 ITEM 12.
    
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS.
  
 ITEM 13.
    
    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.
  
 ITEM 14.
    
    PRINCIPAL ACCOUNTING FEES AND SERVICES.
   31




---



##### Table of Contents



PART IV
 
 ITEM 15.
    
    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
  (1)
    
    Index to Financial Statements
 Reports of Independent Registered Public Accounting Firms
    
    F-1 and F-2Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009
    
    
    F-3Consolidated Statements of Operations for the Nine Months Ended
September 30, 2010, the Year Ended December 31, 2009 and the period
from inception (April 11, 2005 to September 30, 2010
    
    
    F-4Consolidated Statements of Stockholders Equity (Deficit) for the period from
inception
(April 11, 2005) to September 30, 2010
    
    
    F-5Consolidated Statements of Cash Flows for the Nine Months Ended
September 30, 2010, the Year Ended December 31, 2009 and the period
from inception (April 11, 2005) to September 30, 2010
    
    
    F-6Notes to Consolidated Financial Statements
    
    
    F-7
 (2)
    
    Financial Statement Schedules
  (3)
    
    Index to Exhibits
   32




---



##### Table of Contents



Silberstein Ungar, PLLC
CPAs and Business Advisors phone (248) 203-0080
fax (248) 281-0940
30600 Telegraph Road, Suite 2175
Bingham Farms, MI 48025
www.sucpas.com REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Stockholders

Robertson Global Health Solutions Corporation We have audited the accompanying consolidated balance sheet of Robertson Global Health Solutions Corporation and
Subsidiaries (a development stage company) as of September 30, 2010, and the related consolidated statements of
operations, stockholders deficit, and cash flows for the nine months ended September 30, 2010 and for the period from
April 11, 2005 (inception) through September 30, 2010. These consolidated financial statements are the responsibility
of the entitys management. Our responsibility is to express an opinion on these consolidated financial statements
based on our audit. The consolidated financial statements of Robertson Global Health Solutions Corporation and
Subsidiaries as of December 31, 2009 were audited by other auditors whose report dated March 10, 2010 raised
substantial doubt that the Company would continue as a going concern. We did not audit the consolidated financial
statements for the period April 11, 2005 (inception) through December 31, 2009. Those statements were audited by other
auditors whose report has been furnished to us, and our opinion on the consolidated statements of operations,
stockholders deficit, and cash flows for the period April 11, 2005 (inception) through December 31, 2009, insofar as
it relates to the amounts for prior periods through December 31, 2009 is based solely on the report of the other
auditors. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United
States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audit provide a reasonable basis for our opinion. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
financial position of Robertson Global Health Solutions Corporation as of September 30, 2010, and the results of its
operations and its cash flows for the nine months ended September 30, 2010, in conformity with accounting principles
generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As
discussed in Note 1 to the financial statements, the entity has suffered recurring losses from operations and has a net
capital deficiency that raise substantial doubt about its ability to continue as a going concern. Managements plans in
regard to these matters are also described in Note 1. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty. /s/ Silberstein Ungar, PLLC Bingham Farms, MI

December 29, 2010 (MSI LOGO)




---



##### Table of Contents



(WF LOGO)ROBERT E. LIST, CPASTEWART J. REID, CPAMICHAEL L. HANISKO, CPADAVID D. QUIMBY, CPAKATHLYN M. ENGELHARDT, CPARENAE M. CLEVENGER, CPAAMY L RODRIGUEZ, CPASCOTT A. NIETZKE, CPAWALTER G WEINLANDER, CPAROY A. SCHAIRER, CPAJAMES L WHALEY, CPAJEROME L. YANTZ, CPAPHILIP T. SOUTHGATE, CPAROBERT J DUYCK, CPA
 WEINLANDER FITZHUGH
 
 INDEPENDENT AUDITORS REPORT
  
     
 1600 CENTER AVENUEPOST OFFICE BOX 775BAY CITY, MI 48707-0775989-893-5577800-624-2400FAX 989-895-5842www wf-cpas.comwf@wf-cpas.comOFFICES: BAY CITY, CLAREGLADWIN AND WEST BRANCH
    F-2




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION
(a development stage company)
 
 Consolidated Balance Sheets
 September 30,
    
    
    December 31,2010
    
    
    2009ASSETSCurrent assetsCash
    
    $
    40,976
    
    
    $
    35,333Accounts receivables  related parties
    
    
    8,842
    
    
    
    88,000Prepaid and other
    
    
    27,268
    
    
    
    Total current assets
    
    
    77,086
    
    
    
    123,333Property and equipment, net
    
    
    4,114
    
    
    
    3,380Real estate held for sale, net
    
    
    696,625
    
    
    
    Total assets
    
    $
    777,825
    
    
    $
    126,713LIABILITIES AND STOCKHOLDERS DEFICITCurrent liabilitiesAccounts payable
    
    $
    584,279
    
    
    $
    1,261,497Accrued liabilities
    
    
    354,633
    
    
    
    326,711Deposits
    
    
    3,747
    
    
    
    Related party deferred revenue
    
    
    207,416
    
    
    
    207,416Stockholder advances
    
    
    150,000
    
    
    
    Notes payable directors and stockholders  net
    
    
    814,826
    
    
    
    492,748Notes payable other  net
    
    
    476,743
    
    
    
    231,983Convertible notes payable  net
    
    
    
    
    
    
    265,792Warrant liability
    
    
    
    
    
    
    234,035Current portion of facility exit liability
    
    
    51,056
    
    
    
    Current portion bank financing
    
    
    50,000
    
    
    
    250,000Total current liabilities
    
    
    2,692,700
    
    
    
    3,270,182Long-term debtBank term note
    
    
    187,499
    
    
    
    Facility exit liability
    
    
    31,098
    
    
    
    Total long-term debt
    
    
    218,597
    
    
    
    Stockholders deficitPreferred stock, $0.001 par value, 1,000,000 shares authorized,
none issued and outstanding
    
    
    
    
    
    
    Common stock, $0.001 par value, authorized 20,000,000,
11,543,369 and 10,000,000 shares issued and
outstanding, respectively
    
    
    11,543
    
    
    
    10,000Paid in capital
    
    
    11,922,729
    
    
    
    7,178,844Deficit accumulated during development stage
    
    
    (14,067,744
    )
    
    
    (10,332,313
    )Total stockholders deficit
    
    
    (2,133,472
    )
    
    
    (3,143,469
    )Total liabilities and stockholders deficit
    
    $
    777,825
    
    
    $
    126,713
   F-3




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION
(a development stage company)
 
 Consolidated Statements of Operations
 Nine-Month
    
    
    Nine-Month
    
    
    
    
    
    
    April 11, 2005Transition
    
    
    Comparative
    
    
    Year
    
    
    (date ofPeriod Ended
    
    
    Period Ended
    
    
    Ended
    
    
    inception) toSeptember 30,
    
    
    September 30,
    
    
    December 31,
    
    
    September 30,2010
    
    
    2009
    
    
    2009
    
    
    2010(Unaudited)RevenuesContract fees
    
    $
    
    
    
    $
    
    
    
    $
    133,000
    
    
    $
    133,000Operating expensesCost of revenues
    
    
    
    
    
    
    
    
    
    
    139,536
    
    
    
    139,536Product and content development
    
    
    522,908
    
    
    
    528,313
    
    
    
    634,039
    
    
    
    5,543,957Selling, general and administrative
    
    
    1,363,027
    
    
    
    818,615
    
    
    
    1,105,797
    
    
    
    6,654,686Impairment expense on real estate held for sale
    
    
    1,548,375
    
    
    
    
    
    
    
    
    
    
    
    1,548,375Total operating expenses
    
    
    3,434,310
    
    
    
    1,346,928
    
    
    
    1,879,372
    
    
    
    13,886,554Operating loss
    
    
    (3,434,310
    )
    
    
    (1,346,928
    )
    
    
    (1,746,372
    )
    
    
    (13,753,554
    )Other income (expense)Unrealized gain on derivative revaluation
    
    
    12,658
    
    
    
    2,586
    
    
    
    4,621
    
    
    
    17,279Interest and other income
    
    
    15,254
    
    
    
    262,088
    
    
    
    262,088
    
    
    
    310,234Other expenses
    
    
    (29,953
    )
    
    
    
    
    
    
    
    
    
    
    (93,272
    )Interest expense
    
    
    (299,080
    )
    
    
    (71,597
    )
    
    
    (95,389
    )
    
    
    (548,431
    )Total other income
(expense)
    
    
    (301,121
    )
    
    
    193,077
    
    
    
    171,320
    
    
    
    (314,190
    )Net loss
    
    $
    (3,735,431
    )
    
    $
    (1,153,851
    )
    
    $
    (1,575,052
    )
    
    $
    (14,067,744
    )Loss per share (basic)
    
    $
    (0.35
    )
    
    $
    (0.12
    )
    
    $
    (0.16
    )
    
    $
    (1.40
    )Weighted average number of common
shares outstanding
    
    
    10,680,144
    
    
    
    10,000,000
    
    
    
    10,000,000
    
    
    
    10,069,239
   F-4




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION
(a development stage company)
 
 Consolidated Statements of Stockholders Deficit
 Additional
    
    
    
    
    
    
    TotalCommon Stock
    
    
    Paid-In
    
    
    Accumulated
    
    
    EquityShares
    
    
    Dollars
    
    
    Capital
    
    
    Deficit
    
    
    (Deficit)Balances, April 11, 2005 (date of inception)
    
    
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    Stock issued to founder for technology
    
    
    9,600,000
    
    
    
    9,600
    
    
    
    (9,600
    )
    
    
    
    
    
    
    Founder stock assigned to director
    
    
    290,000
    
    
    
    290
    
    
    
    (290
    )
    
    
    
    
    
    
    Sale of stock for cash at $2.50 to $3.25 per share
    
    
    1,156,000
    
    
    
    1,156
    
    
    
    3,348,844
    
    
    
    
    
    
    
    3,350,000Forfeiture of founder stock  net
    
    
    (1,046,000
    )
    
    
    (1,046
    )
    
    
    1,046
    
    
    
    
    
    
    
    Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,373,347
    )
    
    
    (1,373,347
    )Balances, December 31, 2005
    
    
    10,000,000
    
    
    $
    10,000
    
    
    $
    3,340,000
    
    
    $
    (1,373,347
    )
    
    $
    1,976,653Sale of stock at $2.50 to $4.00 per share
    
    
    456,500
    
    
    
    456
    
    
    
    1,759,544
    
    
    
    
    
    
    
    1,760,000Repurchase of stock at $2.50 per share
    
    
    (144,000
    )
    
    
    (144
    )
    
    
    (359,856
    )
    
    
    
    
    
    
    (360,000
    )Forfeiture of founder stock  net
    
    
    (312,500
    )
    
    
    (312
    )
    
    
    312
    
    
    
    
    
    
    
    Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (3,488,381
    )
    
    
    (3,488,381
    )Balances, December 31, 2006
    
    
    10,000,000
    
    
    $
    10,000
    
    
    $
    4,740,000
    
    
    $
    (4,861,728
    )
    
    $
    (111,728
    )Sale of stock at $2.00 to $6.00 per share
    
    
    414,038
    
    
    
    414
    
    
    
    1,089,586
    
    
    
    
    
    
    
    1,090,000Forfeiture of founder stock
    
    
    (414,038
    )
    
    
    (414
    )
    
    
    414
    
    
    
    
    
    
    
    Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (2,451,762
    )
    
    
    (2,451,762
    )Balances, December 31, 2007
    
    
    10,000,000
    
    
    $
    10,000
    
    
    $
    5,830,000
    
    
    $
    (7,313,490
    )
    
    $
    (1,473,490
    )Sale of stock at $2.00 to $3.25 per share
    
    
    658,154
    
    
    
    658
    
    
    
    1,158,342
    
    
    
    
    
    
    
    1,159,000Forfeiture of founder stock
    
    
    (658,154
    )
    
    
    (658
    )
    
    
    658
    
    
    
    
    
    
    
    Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,443,771
    )
    
    
    (1,443,771
    )Balances, December 31, 2008
    
    
    10,000,000
    
    
    $
    10,000
    
    
    $
    6,989,000
    
    
    $
    (8,757,261
    )
    
    $
    (1,758,261
    )Sale of stock at $1.00 per share
    
    
    428,500
    
    
    
    428
    
    
    
    428,072
    
    
    
    
    
    
    
    428,500Classification of 416,000 warrants as a liability
    
    
    
    
    
    
    
    
    
    
    (238,656
    )
    
    
    
    
    
    
    (238,656
    )Forfeiture of founder stock
    
    
    (428,500
    )
    
    
    (428
    )
    
    
    428
    
    
    
    
    
    
    
    Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (1,575,052
    )
    
    
    (1,575,052
    )Balances, December 31, 2009
    
    
    10,000,000
    
    
    $
    10,000
    
    
    $
    7,178,844
    
    
    $
    (10,332,313
    )
    
    $
    (3,143,469
    )Sale of stock at $1.00 per share
    
    
    125,000
    
    
    
    
    
    
    
    125,000
    
    
    
    
    
    
    
    125,000Classification of 125,000 warrants as a liability
    
    
    
    
    
    
    
    
    
    
    (69,497
    )
    
    
    
    
    
    
    (69,497
    )Forfeiture of founder stock
    
    
    (125,000
    )
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Record beneficial conversion of $170,000 of convertible notes
    
    
    
    
    
    
    
    
    
    
    89,048
    
    
    
    
    
    
    
    89,048Redemption of stock
    
    
    (3,076
    )
    
    
    (3
    )
    
    
    (11,997
    )
    
    
    
    
    
    
    (12,000
    )Shares issued on conversion of convertible debt at $1.00 per share
    
    
    3,076
    
    
    
    3
    
    
    
    3,073
    
    
    
    
    
    
    
    3,076Merger related equity transactions:Historical ASI Technology shares
    
    
    1,154,248
    
    
    
    1,154
    
    
    
    2,718,773
    
    
    
    
    
    
    
    2,719,927Shares issued on conversion of convertible
debt at $1.00 per share
    
    
    214,223
    
    
    
    214
    
    
    
    214,009
    
    
    
    
    
    
    
    214,223Reclassification of warrant liability to equity
    
    
    
    
    
    
    
    
    
    
    379,922
    
    
    
    
    
    
    
    379,922Value of 100,000 warrants issued to founder
related to debt extinguishment
    
    
    
    
    
    
    
    
    
    
    250,000
    
    
    
    
    
    
    
    250,000Capital contribution from related party debt
extinguishment
    
    
    
    
    
    
    
    
    
    
    510,000
    
    
    
    
    
    
    
    510,000Value of 51,041 warrants issued to
stockholders related to debt restructuring and
guarantee
    
    
    
    
    
    
    
    
    
    
    55,750
    
    
    
    
    
    
    
    55,750Shares issued on conversion of convertible debt at $1.00 per share
    
    
    175,698
    
    
    
    176
    
    
    
    175,522
    
    
    
    
    
    
    
    175,698Payment of fractional shares on reverse stock split
    
    
    (800
    )
    
    
    (1
    )
    
    
    (4,320
    )
    
    
    
    
    
    
    (4,321
    )Stock based compensation
    
    
    
    
    
    
    
    
    
    
    308,602
    
    
    
    
    
    
    
    308,602Net loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (3,735,431
    )
    
    
    (3,735,431
    )Balances, September 30, 2010
    
    
    11,543,369
    
    
    $
    11,543
    
    
    $
    11,922,729
    
    
    $
    (14,067,744
    )
    
    $
    (2,133,472
    )
   F-5




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION
(a development stage company)
 
 Consolidated Statements of Cash Flows
 Nine-Month
    
    
    Nine-Month
    
    
    
    
    
    
    April 11, 2005Transition
    
    
    Comparative
    
    
    Year
    
    
    (date ofPeriod Ended
    
    
    Period Ended
    
    
    Ended
    
    
    inception) toSeptember 30,
    
    
    September 30,
    
    
    December 31,
    
    
    September 30,2010
    
    
    2009
    
    
    2009
    
    
    2010(Unaudited)Operating activitiesNet loss
    
    $
    (3,735,431
    )
    
    $
    (1,153,851
    )
    
    $
    (1,575,052
    )
    
    $
    (14,067,744
    )Adjustments to reconcile net loss to net
cash used by operating activities:Depreciation
    
    
    3,512
    
    
    
    6,307
    
    
    
    8,409
    
    
    
    42,178Amortization of deferred rent and facility exit liability
    
    
    (14,373
    )
    
    
    
    
    
    
    
    
    
    
    (14,373
    )Adjustment of accrued facility exit liability
    
    
    29,953
    
    
    
    
    
    
    
    
    
    
    
    29,953Unrealized gain on derivative revaluation
    
    
    (12,658
    )
    
    
    (2,586
    )
    
    
    (4,621
    )
    
    
    (17,279
    )Impairment expense
    
    
    1,548,375
    
    
    
    
    
    
    
    
    
    
    
    1,548,375Gain on debt cancellation
    
    
    
    
    
    
    (262,088
    )
    
    
    (262,088
    )
    
    
    (262,088
    )Note discount accretion
    
    
    101,410
    
    
    
    
    
    
    
    
    
    
    
    101,410Beneficial conversion of convertible debt
    
    
    89,048
    
    
    
    
    
    
    
    
    
    
    
    89,048Value of warrants issued for note guarantee
    
    
    16,384
    
    
    
    
    
    
    
    
    
    
    
    16,384Stock based compensation
    
    
    308,602
    
    
    
    
    
    
    
    
    
    
    
    308,602Changes in:Accounts receivable  related parties
    
    
    84,758
    
    
    
    
    
    
    
    (83,000
    )
    
    
    (3,242
    )Prepaid and other
    
    
    (19,991
    )
    
    
    
    
    
    
    
    
    
    
    (19,991
    )Accounts payable and accrued expenses
    
    
    727,606
    
    
    
    799,220
    
    
    
    1,054,805
    
    
    
    3,125,468Deposits
    
    
    (3,747
    )
    
    
    
    
    
    
    
    
    
    
    (3,747
    )Deferred revenue
    
    
    
    
    
    
    50,000
    
    
    
    207,416
    
    
    
    207,416Stockholder advances
    
    
    150,000
    
    
    
    
    
    
    
    
    
    
    
    150,000Accrued interest
    
    
    59,843
    
    
    
    55,082
    
    
    
    76,697
    
    
    
    215,379Net cash used by operating activities
    
    
    (666,709
    )
    
    
    (507,916
    )
    
    
    (577,434
    )
    
    
    (8,554,251
    )Investing activitiesPurchase of property and equipment
    
    
    (3,922
    )
    
    
    
    
    
    
    
    
    
    
    (45,969
    )Proceeds from sale of assets
    
    
    300,000
    
    
    
    
    
    
    
    
    
    
    
    300,000Cash received in merger transaction
    
    
    243,296
    
    
    
    
    
    
    
    
    
    
    
    243,296Net cash provided by investing activities
    
    
    539,374
    
    
    
    
    
    
    
    
    
    
    
    497,327Financing activitiesSale of common stock
    
    
    125,000
    
    
    
    261,000
    
    
    
    428,500
    
    
    
    7,912,500Repurchase of common stock
    
    
    (12,000
    )
    
    
    
    
    
    
    
    
    
    
    (372,000
    )Payment of fractional shares
    
    
    (4,321
    )
    
    
    
    
    
    
    
    
    
    
    (4,321
    )Proceeds from issuance of debt
    
    
    245,000
    
    
    
    250,000
    
    
    
    250,000
    
    
    
    920,416Repayment of debt
    
    
    (220,701
    )
    
    
    (3,604
    )
    
    
    (66,616
    )
    
    
    (358,695
    )Net cash provided by financing activities
    
    
    132,978
    
    
    
    507,396
    
    
    
    611,884
    
    
    
    8,097,900Net increase (decrease) in cash
    
    
    5,643
    
    
    
    (520
    )
    
    
    34,450
    
    
    
    40,976Cash, beginning of period
    
    
    35,333
    
    
    
    883
    
    
    
    883
    
    
    
    Cash, end of period
    
    $
    40,976
    
    
    $
    363
    
    
    $
    35,333
    
    
    $
    40,976SUPPLEMENTAL CASH-FLOW INFORMATIONCash paid for interest
    
    $
    29,100
    
    
    $
    13,510
    
    
    $
    3,190
    
    
    $
    150,435Transfers of liabilities from affiliate for costs incurred
    
    $
    
    
    
    $
    
    
    
    $
    209,135
    
    
    $
    824,053Derivative liability recorded for warrants
    
    $
    (221,377
    )
    
    $
    144,350
    
    
    $
    238,656
    
    
    $
    17,279Issuance of debt in redemption of accrued liabilities
    
    $
    625,632
    
    
    $
    
    
    
    $
    
    
    
    $
    625,632
   F-6




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
 
 Notes to Consolidated Financial Statements
 1. Nature of Operations, Description of Business and Basis of Presentation
 Nature of Operations
   Description of Business
  Development Stage Enterprise
 Accounting and
Reporting by Development Stage Enterprises
 Basis of Presentation
   F-7




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Principles of Consolidation
   Adjustments to Historical Financial Statements
  Fiscal Period
  Use of Estimates in the Preparation of Consolidated Financial Statements
   2. Summary of Significant Accounting Principles
 Cash and Cash Equivalents
  Revenue Recognition
   F-8




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
    Collaborative Arrangements
 Collaborative Arrangements,
 Fair Value of Financial Instruments
  Level 1:
 Level 2:
 Level 3:
  Fixed Assets
  Software Product and Content Development Costs
   F-9




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Real Estate
 Fair Value Measurements and Disclosure
 Facility Exit Liability
 Exit or
Disposal Cost Obligations,
 Warrants Classified as Derivatives
 Derivatives and
Hedging: Contracts in Entitys Own Equity.
  Stock-Based Compensation
   Loss Per Share
  Income Taxes
   F-10




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Recent Accounting Pronouncements
  Revenue Recognition: Multiple-Deliverable Revenue
Arrangements
 Software: Certain Revenue Arrangements That Include
Software Elements
 Revenue RecognitionMilestone Method (Topic 605)
 Fair Value Measurements and Disclosures (Topic
820): Improving Disclosures about Fair Value Measurements
 3. Merger and Recapitalization
    F-11




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
    
    
    At closing approximately $1.3 million was owed by NxOpinion to affiliated non-profit
Robertson Research Institute (RRI), a Colorado nonprofit corporation, and a public
charity as defined in section 501(c)(3) of the Internal Revenue Code. This amount was
reduced by $900,000 at closing through debt forgiveness by RRI and treated as a capital
contribution net of the value of warrants and a tax bonus (Note 6).
 
    
    Secured notes outstanding with five parties with a principal balance of $357,500 (plus
accrued and unpaid interest), effectively demand notes, were exchanged for new unsecured
notes at the same interest rates with a term of June 30, 2011 when all unpaid principal and
interest shall be payable. The holders were also issued warrants for shares of common stock of
the Company on an aggregate basis for 21,450 common shares exercisable at $2.50 per share
for three years.
 
    
    Past consulting fees owed to two management advisors for $243,175 were exchanged for
notes with a 5% annual rate of interest and a term of June 30, 2011 when all unpaid
principal and interest shall be payable. The holders were also issued warrants on an aggregate
of 14,591 common shares of ASIT stock exercisable at $2.50 per share for three years.
 
    
    An obligation related to a $250,000 bank line of credit was assumed by the Company with
Dr. Robertson continuing to guarantee the note. Dr. Robertson was issued warrants on an
aggregate of 15,000 common shares of Company stock exercisable at $2.50 per share for three
years as consideration for his continuing guarantee. In June 2010 this bank line was
converted into a five year term note (Note 8).
 
    
    At closing the Company was obligated on an unsecured installment payment agreement to
NxOpinions legal firm with regard to outstanding legal fees owed for services incurred
through May 28, 2010, with a total outstanding balance of $331,547 at an interest rate of
5% per annum compounded monthly. The installment payment agreement requires the Company to
make minimum monthly payments of principal and interest of $20,000 starting July 31, 2010,
with certain additional amounts payable out of excess cash flows, if available. The entire
outstanding balance is due and payable on December 28, 2010. The
Company is currently in default with respect to this loan and is negotiating revised terms on this note.
   
    
    RGHS sold its direct financing lease interests with a book value of approximately
$330,800 for cash of $280,000. Three directors and/or officers of RGHS, or entities
controlled by them, purchased $150,000 of these interests on the same terms as negotiated
at arms length with unaffiliated parties. These direct financing lease interests related
to the financing and operation of 28 automated teller machines at various locations.
 
    
    RGHS sold its marketable securities consisting of 246,502 restricted shares of common
stock of e.Digital Corporation for $20,000 to an unaffiliated buyer. These securities were
valued each reporting period at market price. The market price for unrestricted shares at
the date of sale was $24,650.
 
    
    The Company assigned its exclusive license agreement with the inventor of U.S. Patent
#6,232,723 related to certain sterilization and decontamination technology in exchange for
$5,500 of debt reduction to an unaffiliated party.
 
    
    Stock option holders exercised 14,667 out-of-the-money stock options at exercise
prices ranging from $3.00 to $6.75 per share for cash of $29,000 and debt reduction of
$23,500. Two directors and one officer of RGHS exercised an aggregate of 8,000 of these
options for proceeds of $25,000.
  F-12




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
     4. Property
and Equipment
  September 30,
    
    
    December 31,2010
    
    
    2009Computer hardware
    
    $
    29,033
    
    
    $
    19,569Vehicle
    
    
    22,478
    
    
    
    22,47851,511
    
    
    
    42,047Accumulated depreciation
    
    
    (47,397
    )
    
    
    (38,667
    )Property and
equipment, net
    
    $
    4,114
    
    
    $
    3,380
 5. Real Estate and Installment Sale
 Real Estate
   F-13




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Determining Fair Value When The Volume And Level Of Activity For The Asset Or Liability Have
Significantly Decreased,
 Installment Sale
  Real Estate Sales
 6. Accounts Payable and Accrued Expenses
  September 30,
    
    
    December 31,2010
    
    
    2009Accounts payablePayable to unrelated parties
    
    $
    66,510
    
    
    $
    Payable to affiliate RRI for contract
services (see Note 16)
    
    
    516,144
    
    
    
    1,258,691Payable to related parties
    
    
    1,625
    
    
    
    2,806Total accounts payable
    
    $
    584,279
    
    
    $
    1,261,497Accrued liabilitiesAccrued wages and vacation
    
    $
    192,206
    
    
    $
    Accrued bonus payable to CEO (see Note 3)
    
    
    140,000
    
    
    
    Accrued consulting fees payable to related
party directors
    
    
    
    
    
    
    237,175Other accounts payable
    
    
    22,427
    
    
    
    89,536Total accrued liabilities
    
    $
    354,633
    
    
    $
    326,711
   F-14




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 7. Facility Exit Liability and Costs
 Exit or Disposal Cost Obligation
  Accrual balance at May 28, 2010
    
    $
    66,574Accrual correction for cash flow assumptions
    
    
    29,012Accretion expense
    
    
    1,501Payment  net
    
    
    (14,933
    )Accrual balance at September 30, 2010
    
    $
    82,154
   F-15




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 8. Notes Payable
  September 30,
    
    
    December 31,2010
    
    
    2009Notes payable  stockholdersUnsecured notes payable to related
party directors with interest ranging
from 10% to 18% with principal and
interest due June 30, 2011. Includes
accrued interest of $154,317 and
$118,976, respectively. Net of note
discount of $13,148 and $-0-,
respectively.
    
    
    (1
    )
    
    $
    433,669
    
    
    $
    411,476Unsecured notes payable to
stockholders with interest ranging
from 10% to 18% with principal and
interest due June 30, 2011. Includes
accrued interest of $23,228 and
$16,272, respectively. Net of note
discount of $2,922 and $-0-
respectively.
    
    
    (2
    )
    
    
    85,306
    
    
    
    81,272Unsecured notes payable issued at
Merger for prior consulting fees owed
to two directors. Principal and
interest at 5% per annum is due on
June 30, 2011. Includes accrued
interest of $4,164. Net of note
discount of $10,933.
    
    
    (3
    )
    
    
    236,406
    
    
    
    Unsecured 11% note payable resulting
from non-conversion of convertible
note issued in April 2009. This note
is currently in default with the
default interest rate being 16%.
Includes accrued interest of $9,445.
(see Note 9)
    
    
    
    
    
    
    59,445
    
    
    
    Total notes payable  directors and
stockholders (current)
    
    
    
    
    
    $
    814,826
    
    
    $
    492,748Notes payable  otherBank note payable due in monthly
installments of $413, including
interest of 3.97% with a maturity of
July 2010. Note was secured by
vehicle.
    
    
    
    
    
    $
    
    
    
    $
    1,231Unsecured installment note, at 5%
compounded monthly, with minimum
monthly payments of $20,000 commencing
July 2010 with the balance due
December 28, 2010. Includes accrued
interest of $0 and $4,496,
respectively.
    
    
    (4
    )
    
    
    476,743
    
    
    
    230,752Five year term bank debt with interest
at prime plus 1%, with monthly
installments of $4,167. Note is
guaranteed by the Companys CEO.
Includes accrued interest of $-0- and
$-0-, respectively.
    
    
    (5
    )
    
    
    237,499
    
    
    
    250,000Total notes payable  other
    
    
    
    
    
    
    714,242
    
    
    
    481,983Long-term portion of bank term debt
    
    
    
    
    
    
    187,499
    
    
    
    Notes payable  other (current portion)
    
    
    
    
    
    $
    526,743
    
    
    $
    481,983
  F-16




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
  09/30/2011
    
    $
    526,74309/30/2012
    
    
    50,00009/30/2013
    
    
    50,00009/30/2014
    
    
    50,00009/30/2015
    
    
    37,499Total
    
    $
    714,242
 (1)
    
    Effective as of the Merger on May 28, 2010 new unsecured notes at the same interest rates
were issued for previous secured notes with no stated repayment date. The Company issued
warrants exercisable for 17,550 common shares at $2.50 per share
until May 28, 2013 for the note restructuring. The value of the warrants of $19,169 is a note discount
being amortized to interest expense over the term of the notes.(2)
    
    Effective as of the Merger on May 28, 2010 new unsecured notes at the same interest rates
were issued for previous secured notes with no stated repayment date. The Company issued
warrants exercisable for 3,900 common shares at $2.50 per share until
May 28, 2013 for the note restructuring. The value of the warrants of $4,260 is a note discount
being amortized to interest expense over the term of the notes.(3)
    
    The Company issued warrants exercisable for 14,591 common shares at $2.50 per share until May
28, 2013 for converting consulting fees for unsecured notes. The value of the
warrants of $15,937 is a note discount being amortized over the term of the notes.(4)
    
    New unsecured note issued at Merger effective May 28, 2010 to replace prior secured notes and
payables related to legal fees. The company is currently negotiating revised terms on this
note.(5)
    
    The Company issued warrants exercisable for 15,000 common shares at $2.50 per share until May
28, 2013 to Dr. Robertson for his continuing guarantee of a bank line of
credit (due through affiliate RRI) that has been renegotiated as a term loan. The value of the
warrants of $16,384 was a note discount expensed to interest at issuance as the note was due immediately
until subsequently renegotiated as a five year term note. 9. Convertible Notes Payable
    10. Stockholders Deficit
   F-17




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
     11. Stock Options and Stock Purchase Warrants
 Stock Option Plan
   Stock-Based Compensation
   Nine Months EndedSeptember 30, 2010Expected Volatility
    
    
    71%Risk-free interest rate
    
    
    1.14%Forfeiture rate
    
    
    0.0%-5.0%Dividend yield
    
    
    0.0%Expected life in years
    
    
    4.2
  F-18




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Share-Based Payment: Certain
Assumptions Used in Valuation Methods  Expected Term
   Stock Option Summary Information
  September 30, 2010Weighted-Weighted-
    
    
    Aggregate
    
    
    AverageAverage
    
    
    Intrinsic Value
    
    
    LifeShares
    
    
    Exercise Price
    
    
    (2)
    
    
    (Years)Outstanding beginning of period
    
    
    Assumed May 28, 2010 from Merger
    
    
    25,012
    
    
    $
    5.41Granted
    
    
    566,400
    
    
    $
    3.13Exercised
    
    
    Cancelled
    
    
    (1,334
    )
    
    $
    5.25Outstanding end of period (1)
    
    
    590,078
    
    
    $
    3.22
    
    
    $
    153,960
    
    
    
    4.8Options exercisable at end of period
    
    
    216,958
    
    
    $
    3.44
    
    
    $
    40,072
    
    
    
    4.6
 (1)
    
    Options outstanding are exercisable at prices ranging from $3.00 to $6.75 and expire
over the period 2011 to 2015.(2)
    
    Aggregate intrinsic value is based on the closing price of the Companys common stock
on September 30, 2010 of $3.40.  Weighted averageNumber
    
    
    
    
    
    
    
    
    
    
    Weighted
    
    
    exercise price ofoutstanding at
    
    
    
    
    
    
    Weighted
    
    
    average
    
    
    options exercisableRange of exercise
    
    September 30,
    
    
    Number exercisable at
    
    
    average
    
    
    remaining
    
    
    at September 30,prices
    
    2010
    
    
    September 30, 2010
    
    
    exercise price
    
    
    contractual life
    
    
    2010$
    
    #
    
    
    #
    
    
    $
    
    
    Years
    
    
    $$3.00
    
    
    
    359,901
    
    
    
    75,181
    
    
    
    3.00
    
    
    
    4.9
    
    
    
    3.00$3.30-$3.40
    
    
    
    210,500
    
    
    
    122,100
    
    
    
    3.35
    
    
    
    4.9
    
    
    
    3.32$3.75-$6.75
    
    
    
    19,677
    
    
    
    19,677
    
    
    
    5.91
    
    
    
    1.9
    
    
    
    5.91
  F-19




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Warrants
  Derivatives and Hedging: Contracts in
Entitys Own Equity,
    AverageExercisePrice PerNumber
    
    
    ShareShares purchasable under outstanding warrants at January 1, 2009
    
    
    
    
    
    
    Stock purchase warrants granted with equity sales
    
    
    416,000
    
    
    $
    1.00Shares purchasable under outstanding warrants at December 31, 2009
    
    
    416,000
    
    
    $
    1.00Stock purchase warrants granted with equity sales
    
    
    125,000
    
    
    $
    1.00Stock purchase warrants granted with convertible notes
    
    
    170,000
    
    
    $
    2.50Stock purchase warrants granted in connection with debt restructuring
    
    
    51,041
    
    
    $
    2.50Stock purchase warrants granted for prior services
    
    
    100,000
    
    
    $
    0.01Shares purchasable under outstanding warrants at September 30, 2010
    
    
    862,041
    
    
    $
    1.27
  Number of
    
    
    Exercise PriceDescription
    
    Common Shares
    
    
    Per Share
    
    
    Expiration DateWarrants
    
    
    541,000
    
    
    $
    1.00
    
    
    December 31, 2014Warrants
    
    
    170,000
    
    
    $
    2.50
    
    
    March 31, 2013Warrants
    
    
    51,041
    
    
    $
    2.50
    
    
    May 28, 2013Warrants
    
    
    100,000
    
    
    $
    0.01
    
    
    May 28, 2013862,041
  F-20




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 12. Simple IRA
   13. Operating Lease
  09/30/2011
    
    $
    85,94409/30/2012
    
    
    64,458Total
    
    $
    150,402
 14. Fair Value Measurements
  Fair Value Measurements and Disclosures
 Assets and Liabilities Measured at Fair Value on a Recurring Basis
  Fair Value Measurements UsingQuoted Pricesin Active
    
    
    SignificantMarkets for
    
    
    Other
    
    
    SignificantIdentical
    
    
    Observable
    
    
    UnobservableAssets
    
    
    Inputs
    
    
    InputsTotal
    
    
    Level 1
    
    
    Level 2
    
    
    Level 3December 31, 2009:Assets:None
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    Liabilities:Warrant liability
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    234,035September 30, 2010:Assets:None
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    Liabilities:Warrant liability
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
  F-21




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Derivatives
and Hedging: Contracts in Entitys Own Equity,
  Balance at January 1, 2009
    
    $
    Issuance of new warrant derivatives from sale of member units
    
    
    238,656Adjustment to fair value included in other income
    
    
    (4,621
    )Balance at December 31, 2009
    
    
    234,035Issuance of new warrant derivatives from sale of member units
    
    
    69,497Issuance of new warrant derivatives in connection with convertible notes
    
    
    89,048Adjustment to fair value included in other income
    
    
    (12,658
    )Reclassification of warrant liability to equity
    
    
    (379,922
    )Balance at September 30, 2010
    
    $
    
 Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
  Fair Value Measurements UsingQuoted Prices
    
    
    Significantin Active
    
    
    Other
    
    
    SignificantMarkets for
    
    
    Observable
    
    
    UnobservableIdentical Assets
    
    
    Inputs
    
    
    Inputs
    
    
    Total GainsTotal
    
    
    Level 1
    
    
    Level 2
    
    
    Level 3
    
    
    (Losses)September 30, 2010:Assets:Real estate held for sale
    
    $
    696,625
    
    
    $
    
    
    
    $
    
    
    
    $
    696,625
    
    
    $
    (1,548,375
    )Liabilities:None
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    F-22




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
 Determining Fair Value When The Volume And Level Of Activity For The Asset Or Liability Have
Significantly Decreased,
 15. Income Taxes
    Nine Months Ended
    
    
    Year EndedSeptember 30,
    
    
    December 31,2010
    
    
    2009
    
    
    2009Income taxes (benefit) computed at federal statutory rate
    
    $
    (1,216,000
    )
    
    $
    
    
    
    $
    NxOpinion LLC results not subject to corporate income taxes
    
    
    342,000
    
    
    
    
    
    
    
    Corporate losses prior to Merger
    
    
    (121,000
    )
    
    
    
    
    
    
    Permanent book-tax differences
    
    
    228,000
    
    
    
    
    
    
    
    State income taxes, net of federal effect
    
    
    
    
    
    
    
    
    
    
    State tax credit
    
    
    
    
    
    
    
    
    
    
    Deferred income tax valuation allowance
    
    
    767,000
    
    
    
    
    
    
    
    Income tax provision
    
    $
    
    
    
    $
    
    
    
    $
    
  F-23




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
  September 30,2010Deferred tax assets:Net operating loss carryforwards
    
    $
    1,112,000Capital loss carryforward
    
    
    182,000Impairment and bad debt reserves
    
    
    526,000Stock-based compensation
    
    
    169,000Accruals and other
    
    
    73,0002,062,000Valuation allowance for deferred tax assets
    
    
    (2,062,000
    )Net deferred taxes
    
    $
    
     16. Related Party Transactions
   F-24




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
  Nine Months Ended
    
    
    Year EndedSeptember 30,
    
    
    December 31,2010
    
    
    2009
    
    
    2009(Unaudited)Personnel and benefits
    
    $
    603,666
    
    
    $
    772,652
    
    
    $
    1,077,738Professional fees
    
    
    185,195
    
    
    
    201,793
    
    
    
    202,046Occupancy
    
    
    61,948
    
    
    
    76,470
    
    
    
    108,828Travel and entertainment
    
    
    36,016
    
    
    
    67,107
    
    
    
    82,221Marketing
    
    
    5,961
    
    
    
    
    
    
    
    Insurance
    
    
    49,025
    
    
    
    23,015
    
    
    
    28,354Interest
    
    
    11,585
    
    
    
    16,515
    
    
    
    22,945Computer and software
    
    
    2,635
    
    
    
    154,407
    
    
    
    159,925Consulting and contract services
    
    
    9,608
    
    
    
    9,175
    
    
    
    12,300Other
    
    
    26,429
    
    
    
    17,316
    
    
    
    22,802$
    992,068
    
    
    $
    1,338,450
    
    
    $
    1,717,159
   17. Commitments and Contingencies
    F-25




---



##### Table of Contents



ROBERTSON GLOBAL HEALTH SOLUTIONS CORPORATION AND SUBSIDIARIES
(a development stage company)
Notes to Consolidated Financial Statements
   18. Subsequent Events
   F-26




---



##### Table of Contents



INDEX TO EXHIBITS
 ExhibitNumber
    
    Description2.1
    
    
    Agreement and Plan of Recapitalization by and among ASI Technology
Corporation, Nx Acquisition Corp and NxOpinion, LLC dated May 28, 2010
(previously filed as Exhibit 2.01 to our Current Report on Form 8-K filed
on June 4, 2010 and incorporated herein by reference)3.1
    
    
    Articles of Incorporation, as currently in effect (previously filed as
Exhibit 3.1 to our Quarterly Report on Form 10-Q filed on August 16, 2010
and incorporated herein by reference)3.2
    
    
    Amended and Restated Bylaws (previously filed as Exhibit 3.01 to our
Current Report on Form 8-K filed on June 4, 2010 and incorporated herein by
reference)4.1
    
    
    Form of Stock Purchase Warrant dated May 28, 2010 between the Company and
twelve stockholders on an aggregate of 541,000 common shares exercisable at
$1.00 per share until December 31, 2014 (previously filed as Exhibit 4.1 to
our Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)4.2
    
    
    Form of Stock Purchase Warrant dated May 28, 2010 between the Company and
two stockholders on an aggregate of 170,000 common shares exercisable at
$2.50 per share until March 31, 2013 (previously filed as Exhibit 4.2 to
our Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)4.3
    
    
    Form of Stock Purchase Warrant dated May 28, 2010 between the Company and
five note holders and one director guarantor on an aggregate of 51,041
common shares exercisable at $2.50 per share until May 28, 2013 (previously
filed as Exhibit 4.3 to our Quarterly Report on Form 10-Q filed on August
16, 2010 and incorporated herein by reference)4.4
    
    
    Stock Purchase Warrant dated May 28, 2010 between the Company and Dr.
Robertson on an aggregate of 100,000 common shares exercisable at $0.01 per
share until May 28, 2013 (previously filed as Exhibit 4.4 to our Quarterly
Report on Form 10-Q filed on August 16, 2010 and incorporated herein by
reference)10.1
    
    
    Form of 11% Bridge Notes due June 30, 2010 between the Company and one
shareholder dated April 28 and May 10, 2010 for an aggregate of $75,000
(previously filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q
filed on August 16, 2010 and incorporated herein by reference)10.2
    
    
    Form of 11% Convertible Note due June 30, 2010 between the Company and two
shareholders dated February 19, 2010 and March 19, 2010 for an aggregate of
$170,000 (previously filed as Exhibit 10.2 to our Quarterly Report on Form
10-Q filed on August 16, 2010 and incorporated herein by reference)10.3
    
    
    Form of Amended and Restated Promissory Notes due June 30, 2011 with
interest rates of 10% to 18% between the Company and five creditors dated
May 28, 2010 for an aggregate of $357,500 of principal and prior accrued
interest and due June 30, 2011 (previously filed as Exhibit 10.3 to our
Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)10.4
    
    
    Form of Promissory Notes due June 30, 2011 with an interest rate of 5%
between the Company and two director consultants dated May 28, 2010 for an
aggregate of $243,175 (previously filed as Exhibit 10.4 to our Quarterly
Report on Form 10-Q filed on August 16, 2010 and incorporated herein by
reference)10.5
    
    
    Corrected Bank term debt agreement maturing June 1, 2015 between the
Company and Fifth Third Bank dated August 12, 2010 (Replacing original note
dated June 1, 2010, in the principal amount of $250,000 to correct clerical
error) (previously filed as Exhibit 10.5 to our Quarterly Report on Form
10-Q filed on August 16, 2010 and incorporated herein by reference)10.6
    
    
    Unsecured Loan Agreement between the Company and the Michael J. Jandernoa
Trust and Marilyn Hite dated April 3, 2009 (previously filed as Exhibit
10.6 to our Quarterly Report on Form 10-Q filed on August 16, 2010 and
incorporated herein by reference)10.7
    
    
    Unsecured 16% Note Payable due April 2, 2010 for $50,000 between the
Company and Marilyn Hite dated April 3, 2009 (previously filed as Exhibit
10.7 to our Quarterly Report on Form 10-Q filed on August 16, 2010 and
incorporated herein by reference)10.8
    
    
    Unsecured 11% Convertible Note payable due April 2, 2010 for $200,000
between the Company and the Michael J. Jandernoa Trust dated April 3, 2009
(previously filed as Exhibit 10.8 to our Quarterly Report on Form 10-Q
filed on August 16, 2010 and incorporated herein by reference)10.9
    
    
    5% Term note agreement due December 28, 2010 between the Company and
Dickinson Wright, PLLC for $331,547 and dated May 28, 2010 (previously
filed as Exhibit 10.9 to our Quarterly Report on Form 10-Q filed on August
16, 2010 and incorporated herein by reference)




---



##### Table of Contents



ExhibitNumber
    
    Description10.10
    
    
    Amended and Restated License Agreement between the Company and Vanahab
Health Diagnostics effective April 28, 2010 (previously filed as Exhibit
10.10 to our Quarterly Report on Form 10-Q filed on August 16, 2010 and
incorporated herein by reference)10.11
    
    
    Installment Letter Agreement for Water Rights dated June 16, 2010 between
the Company and Davric Corporation (previously filed as Exhibit 10.11 to
our Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)10.12
    
    
    2010 Stock Incentive Plan of the Company adopted February 16, 2010 (filed
as Appendix A to Schedule 14C filed on April 26, 2010, and incorporated
herein by reference)10.13
    
    
    Employment Agreement dated June 3, 2010 between the Company and Dr.
Robertson (previously filed as Exhibit 10.13 to our Quarterly Report on
Form 10-Q filed on August 16, 2010 and incorporated herein by reference)10.14
    
    
    Lease Agreement expiring June 30, 2012 between the Company and Bay Way
Properties, LLC dated July 1, 2010 (previously filed as Exhibit 10.14 to
our Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)10.15
    
    
    Collaboration Agreement expiring December 31, 2012 between the Company and
Microsoft Corporation dated August 14, 2009 (previously filed as Exhibit
10.15 to our Quarterly Report on Form 10-Q filed on August 16, 2010 and
incorporated herein by reference)10.16
    
    
    Product Distribution Agreement between the Company and Aversien Science,
LLC dated March 29, 2010 (previously filed as Exhibit 10.16 to our
Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)10.17
    
    
    Addendum to Product Distribution Agreement between the Company and Aversien
Science, LLC dated March 29, 2010 (previously filed as Exhibit 10.17 to our
Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)10.18
    
    
    License Agreement expiring April 27, 2013 between the Company and Companies
On Text, LLC dated April 28, 2010 (previously filed as Exhibit 10.18 to our
Quarterly Report on Form 10-Q filed on August 16, 2010 and incorporated
herein by reference)10.19
    
    
    Addendum to License Agreement expiring April 27, 2013 between the Company
and Companies On Text, LLC dated April 28, 2010 (previously filed as
Exhibit 10.19 to our Quarterly Report on Form 10-Q filed on August 16, 2010
and incorporated herein by reference)10.20
    
    
    Second Addendum to License Agreement expiring April 27, 2013 between the
Company and Companies On Text, LLC dated April 28, 2010 (previously filed
as Exhibit 10.20 to our Quarterly Report on Form 10-Q filed on August 16,
2010 and incorporated herein by reference)10.21
    
    
    Sublease dated as of October 11, 2007 between ASI Capital Corporation and
Joseph L. Lamarca and Jerry E. Polis (previously filed as Exhibit 99.1 to
our Current Report on Form 8-K filed on November 9, 2007 and incorporated
herin by reference)21.1
    
    
    Subsidiaries (previously filed as Exhibit 21.1 to our Quarterly Report on
Form 10-Q filed on August 16, 2010 and incorporated herein by reference)23.1
    *
    
    Consent of Silberstein Ungar, PLLC23.2
    *
    
    Consent of Weinlander Fitzhugh, Certified Public Accountants and Consultants31.1
    *
    
    Certification of Joel C. Robertson pursuant to Rule 13a-14(a) under the
Securities Exchange Act of
193431.2
    *
    
    Certification of Melissa A. Seeger pursuant to Rule 13a-14(a) under the
Securities Exchange Act of 193432.1
    *
    
    Certifications pursuant to 18 U.S.C. Section 1350.
 
 +
    
    Management contract or compensatory plan or arrangement.*
    
    Filed herewith.




---



##### Table of Contents



SIGNATURES
  Robertson Global Health Solutions CorporationBy:
    /s/ Joel C. RobertsonChairman, President and Chief Executive Officer   Name
    
    Position
    
    Date/s/ Joel C. Robertson

Joel C. Robertson
    
    Chairman, President and 
Chief Executive Officer
(Principal Executive Officer)
    
    December 29, 2010/s/ Melissa A. Seeger

Melissa A. Seeger
    
    Chief Financial Officer, 
Treasurer  and Secretary

(Principal Financial and
Accounting Officer)
    
    December 29, 2010/s/ Gerald L. Ehrens

Gerald L. Ehrens
    
    Director
    
    December 29, 2010Director
    
    December 29, 2010Peter J. Perkinson